We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
- Pivotal Phase 3 LUCIDITY trial will evaluate FDA-agreed upon primary outcome of reduction in hypoglycemia events and designed to align as closely as possible with previous Phase 2 trial designs...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (โAmylyxโ or the โCompanyโ) today announced that management will participate in the 7th Annual Evercore ISI HealthCONx Conference. The conference is...
On track to initiate a Phase 3 program for Companyโs lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia...
ย Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (โAmylyxโ or the โCompanyโ) will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyxโ senior management team will...
- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.35 | -8.55745721271 | 4.09 | 4.15 | 3.73 | 535823 | 3.93892107 | CS |
4 | -1.78 | -32.2463768116 | 5.52 | 5.52 | 3.73 | 753855 | 4.36053522 | CS |
12 | 0.66 | 21.4285714286 | 3.08 | 7.27 | 3.065 | 1308554 | 4.9577737 | CS |
26 | 1.86 | 98.9361702128 | 1.88 | 7.27 | 1.62 | 1348529 | 3.49728315 | CS |
52 | -10.98 | -74.5923913043 | 14.72 | 19.9488 | 1.575 | 1854654 | 4.74514429 | CS |
156 | -17.26 | -82.1904761905 | 21 | 41.9297 | 1.575 | 1336576 | 14.77333672 | CS |
260 | -17.26 | -82.1904761905 | 21 | 41.9297 | 1.575 | 1336576 | 14.77333672 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions